Market Place
Sourcing Support
Acoramidis Reduces All-Cause CV Mortality Risk ATTR-CM
30 Mar 2026 //
GLOBENEWSWIRE
Bridgebio To Showcase Attribute-Cm OLE Trial Data At ACC Sessions
23 Mar 2026 //
GLOBENEWSWIRE
BridgeBio Pharma Grants Inducements Under Nasdaq Rule 5635(c)(4)
20 Mar 2026 //
GLOBENEWSWIRE
Bridgebio To Unveil Phase 3 FORTIFY Trial Data At MDA 2026
04 Mar 2026 //
GLOBENEWSWIRE
BridgeBio Unveils 2025 Financial Results And Commercial Updates
24 Feb 2026 //
GLOBENEWSWIRE
BridgeBio To Participate In March Investor Conferences
23 Feb 2026 //
GLOBENEWSWIRE
BridgeBio Reports Q4, FY 2025 Results and Business Update
17 Feb 2026 //
GLOBENEWSWIRE
BridgeBio Pharma`s Inducement Grants Under Nasdaq Rule 5635(c)(4)
17 Feb 2026 //
GLOBENEWSWIRE
Bridgebio Advances Achondroplasia Drug On Strong Data
13 Feb 2026 //
BIOSPACE
BridgeBio Pharma Awards Inducement Grants Under Nasdaq Rule
27 Jan 2026 //
GLOBENEWSWIRE
BridgeBio Proposes 2033-Due Notes to Prefund 2027 Repayment
14 Jan 2026 //
GLOBENEWSWIRE
BridgeBio: Program Updates, 2026 Milestones at J.P. Morgan Conf
12 Jan 2026 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Rules
19 Nov 2025 //
GLOBENEWSWIRE
Bridgebio To Unveil Encaleret Ph3 Results in ADH1 CALIBRATE Study
28 Oct 2025 //
GLOBENEWSWIRE
Bridgebio Announces Successful Phase 3 Trial Of BBP-418
27 Oct 2025 //
GLOBENEWSWIRE
Bridgebio To Presents BBP-418 Ph 3 Results In LGMD2I/R9 FORTIFY
24 Oct 2025 //
GLOBENEWSWIRE
Bridgebio Pharma Discloses Inducement Grants Per Nasdaq LR
03 Oct 2025 //
GLOBENEWSWIRE
Bridgebio To Present More Attribute-Cm Cardiovascular Data
22 Sep 2025 //
GLOBENEWSWIRE
Encaleret Normalizes Calcium in Phase 2 Hypoparathyroidism Study
06 Sep 2025 //
GLOBENEWSWIRE
SPACs Line Up To Clear Biotech`s IPO Backlog
03 Sep 2025 //
BIOSPACE
BridgeBio to Showcase Extended ATTRibute-CM Data at ESC Congress
25 Aug 2025 //
GLOBENEWSWIRE
Genetics Confirm ADH1-Linked CASR Variants Are Underdiagnosed
23 Jul 2025 //
GLOBENEWSWIRE
BridgeBio Schedules Q2 2025 Financial Results Call for August 5
22 Jul 2025 //
GLOBENEWSWIRE
BridgeBio to Host LGMD2I/R9 Webinar on July 11
26 Jun 2025 //
GLOBENEWSWIRE
Purcell & Lefkowitz LLP Investigates BridgeBio Pharma
23 Apr 2025 //
PR NEWSWIRE
BridgeBio to Present Cardiovascular Outcomes Data at ACC Sessions
24 Mar 2025 //
GLOBENEWSWIRE
BridgeBio Announces CFO Succession
17 Mar 2025 //
GLOBENEWSWIRE
BBOT & Helix To Merge, Creating Public Oncology Biotech Company
28 Feb 2025 //
BUSINESSWIRE
BridgeBio Prices $500M Notes Due 2031 To Refinance Secured Debt
26 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Oncology to Participate in Morgan Health Conference 2025
23 Dec 2024 //
BUSINESSWIRE
BridgeBio touts extension study data for ATTR-CM drug acoramidis
18 Nov 2024 //
FIERCE BIOTECH
BridgeBio Oncology Doses First Patient in Phase 1 BREAKER-101 Trial
30 Oct 2024 //
BUSINESSWIRE
BridgeBio Shares Data From CANaspire Study For Canavan Disease
24 Oct 2024 //
GLOBENEWSWIRE
BridgeBio Shares Recurrent Event Analysis Of ATTRibute-CM Study
27 Sep 2024 //
GLOBENEWSWIRE
BridgeBio`s Infigratinib Gets Breakthrough Therapy Status
17 Sep 2024 //
GLOBENEWSWIRE
BridgeBio Reports Phase 1/2 Results For CAH Gene Therapy
10 Sep 2024 //
GLOBENEWSWIRE
BridgeBio`s BBP-812 Receives FDA`s RMAT Designation For Canavan
10 Sep 2024 //
GLOBENEWSWIRE
BridgeBio to stop development of therapy for genetic disorder
10 Sep 2024 //
REUTERS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Sep 2024 //
GLOBENEWSWIRE
BridgeBio to Present Additional Analyses from ATTRibute-CM Trial at ESC Congress
29 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Launches Offshoot With $300M For Genetic Disease Programs
21 Aug 2024 //
FIERCE BIOTECH
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08 Aug 2024 //
GLOBENEWSWIRE
BridgeBio and Resilience Announce Strategic Multi-Year Partnership
03 Oct 2023 //
BUSINESSWIRE
BridgeBio Presents Encouraging Clinical and Biomarker Data from its BBP-812
22 May 2023 //
GLOBENEWSWIRE
BridgeBio to Present Data its BBP-812 Canavan Disease Gene Therapy Program
15 May 2023 //
GLOBENEWSWIRE
